Document Detail


Amlodipine improves endothelial function and metabolic parameters in patients with hypertension.
MedLine Citation:
PMID:  18199500     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Reciprocal relationships between endothelial dysfunction and insulin resistance imply that improvement in endothelial dysfunction will have beneficial metabolic consequences. We hypothesized that amlodipine therapy in hypertensive subjects will improve endothelial dysfunction and metabolic parameters. METHODS: Amlodipine (10 mg daily for 8 weeks) or placebo was given to each 45 patients with mild to moderate hypertension in a randomized, double-blind, placebo-controlled, and parallel study. Age, sex, and body mass index were matched. RESULTS: Amlodipine therapy significantly reduced systolic and diastolic blood pressure and increased HDL-cholesterol to greater extent than placebo therapy (all P<0.001). Amlodipine therapy significantly improved flow-mediated dilator response to hyperemia and reduced plasma malondialdehyde levels to a greater extent than placebo (P<0.001 and P=0.035). Amlodipine therapy significantly increased plasma adiponectin levels (P=0.009) and decreased plasma leptin and resistin levels (P<0.001 and P=0.025, respectively) to a greater extent than placebo. Correlations were noted between percent changes in adiponectin levels and percent changes in HDL-cholesterol (r=0.348, P=0.019) and QUICKI (r=0.326, P=0.029) following amlodipine therapy. Only changes in HDL-cholesterol (beta=0.469, P=0.019) and QUICKI (beta=1.786, P=0.069) were independent predictors of changes in adiponectin levels (multivariate regression analysis). We also observed inverse correlations between percent changes in leptin levels and percent changes in QUICKI (r=-0.569, P<0.001) following amlodipine therapy with changes in QUICKI (beta=1.810, P<0.001) as an independent predictor of changes in leptin levels. CONCLUSIONS: Amlodipine therapy improves blood pressure, endothelial function, and metabolic parameters in patients with hypertension.
Authors:
Kwang Kon Koh; Seung Hwan Han; Jeong Yeal Ahn; Wook-Jin Chung; Yonghee Lee; Eak Kyun Shin
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-01-15
Journal Detail:
Title:  International journal of cardiology     Volume:  133     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-03-10     Completed Date:  2009-07-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  23-31     Citation Subset:  IM    
Affiliation:
Gil Medical Center, Gachon University, Incheon, Korea. kwangk@gilhospital.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adiponectin / blood
Amlodipine / therapeutic use*
Antihypertensive Agents / therapeutic use*
Biological Markers / blood*
Cholesterol, HDL / blood,  drug effects
Double-Blind Method
Endothelium, Vascular / drug effects*
Female
Humans
Hypertension / drug therapy*,  metabolism
Leptin / blood
Male
Malondialdehyde / blood
Middle Aged
Placebos
Regression Analysis
Resistin / blood
Statistics, Nonparametric
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adiponectin; 0/Antihypertensive Agents; 0/Biological Markers; 0/Cholesterol, HDL; 0/Leptin; 0/Placebos; 0/Resistin; 542-78-9/Malondialdehyde; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic value of heart rate variability in patients with renal failure on hemodialysis.
Next Document:  Metabolic agents in the management of diabetic coronary patients: a new era.